Patritumab Deruxtecan Under Review for Locally Advanced, Metastatic EGFR-Mutated NSCLC

Patritumab deruxtecan is under review to treat previously treated adults with locally advanced or metastatic EGFR-mutated NSCLC.

Related Keywords

Ken Takeshita ,Daiichi Sankyo ,Drug Administration ,Priority Review ,Biologics License Application ,Prescription Drug User Fee Act ,Breakthrough Therapy ,Global Head ,